Product Categories
Contact Us
Contact Person: Garry
Skype: spy3344
Whats app: +86 18702759822
MK 4827 Niraparib Tosylate Cancer Medicine

MK 4827 Niraparib Tosylate Cancer Medicine

Whatsapp:+8618123940985 Skype:shucanlynn Key words,Niraparib Tosylate; CAS 1038915-73-9; MK-4827 Tosylate,MK-4827 dosage,how to take MK-4827,Niraparib is an orally active small molecule PARP inhibitor developed by Tesaro to treat ovarian cancer.

  • Features & Specification

    Product introduction

    Best MK-4827 (Niraparib) Peptides

    Whatsapp:+86 18123940985



    Price: Negotiable

    Customized blend :Available

    Standard: SGS,ISO9001,KOSHER



    Other name:Niraparib

    WhatsApp: +8618123940985


    MF: C19H20N4O
    EINECS No.: 1038915-60-4
    Type: Antineoplastic Agents
    Grade Standard: Medicine Grade
    Usage: Animal Pharmaceuticals
    Brand Name: TwoChem
    Model Number: API
    Purity: 99%
    Name: Niraparib
    Appearance: Off-White Powder
    Grade: Phamaceutical Grade


    What is MK-4827 ?

    MK-4827 also name is Niraparib that is an oral poly(ADP) ribose polymerase (PARP) inhibitor that inhibits DNA damage repair in cells. For cancer cells with BRCA mutations, if PARP activity is inhibited, further division of these cells can produce large amounts of DNA damage, killing cancer still exists BRCA, and normal cells can repair DNA because of PARP, but some of them are of poor quality and live. Not down. This is a PARP inhibitor as a targeted drug that causes cancer cells to selectively kill BRCA mutations.


    Key words,

    Niraparib Tosylate; CAS 1038915-73-9; MK-4827 Tosylate,MK-4827 dosage,how to take MK-4827 

    Niraparib is an orally active small molecule PARP inhibitor developed by Tesaro to treat ovarian cancer.

    Niraparib was granted fast track designation by the US Food and Drug Administration (FDA), and Tesaro submitted a new drug application in 2016. It was approved on 27 March 2017 in the US,but is not approved in Europe as of June 2017.



    Active pharmaceutical ingredients

    Niraparib (MK-4827) is a new potent oral PARP-1 and PARP-2 inhibitor and is currently in phase III clinical trials for the treatment of ovarian cancer. Phase III clinical trials are planned for breast cancer treatment.

    The drug is used in the form of nilapatin hydrochloride tosylate monohydrate, which is a white to non-hygroscopic crystal


    Medical use

    The drug is approved by the FDA for the maintenance of patients with recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. These patients have a complete or partial response to platinum-based chemotherapy. 

    In a study of 553 patients, progression-free survival (PFS) was 21.0 months for patients who were treated with niraparib in germline-negative or suspected BRCA mutations, compared with 5.5 months in the placebo group. Patients who did not have this mutation had a PFS of 9.3 months in the La Palab group under the placebo treatment compared with 3.9 months in the placebo group.


    Side effect

    The most common side effects in the study were low blood cell counts, namely thrombocytopenia (61% of patients, 29% severe), anemia (50%, severe 25%), and neutropenia (30%, severe 20%). Other, mainly mild-to-moderate side effects include nausea, fatigue and constipation. In a study that had run for more than 250 days (median), 15% of patients had to permanently disable Laparab because of adverse reactions.


    SARMs List

    MK-2866 (Ostarine)
    RAD-140 (Testolone)
    MK-677 (Ibutamoren; Nutrobal)
    LGD-4033 (Ligandrol; Anabolicum)
    S4 (Andarine)
    SR9009 (Stenabolic)


    Please feel free contact me

    Whatsapp:+86 18123940985


Hot Tags: MK 4827 niraparib tosylate cancer medicine, China, suppliers, factory, buy, price, quotation, free sample
Related Products